Document Detail


A cell-targeted photodynamic nanomedicine strategy for head and neck cancers.
MedLine Citation:
PMID:  23531079     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Photodynamic therapy (PDT) holds great promise for the treatment of head and neck (H&N) carcinomas where repeated loco-regional therapy often becomes necessary due to the highly aggressive and recurrent nature of the cancers. While interstitial light delivery technologies are being refined for PDT of H&N and other cancers, a parallel clinically relevant research area is the formulation of photosensitizers in nanovehicles that allow systemic administration yet preferential enhanced uptake in the tumor. This approach can render dual-selectivity of PDT, by harnessing both the drug and the light delivery within the tumor. To this end, we report on a cell-targeted nanomedicine approach for the photosensitizer silicon phthalocyanine-4 (Pc 4), by packaging it within polymeric micelles that are surface-decorated with GE11-peptides to promote enhanced cell-selective binding and receptor-mediated internalization in EGFR-overexpressing H&N cancer cells. Using fluorescence spectroscopy and confocal microscopy, we demonstrate in vitro that the EGFR-targeted Pc 4-nanoformulation undergoes faster and higher uptake in EGFR-overexpressing H&N SCC-15 cells. We further demonstrate that this enhanced Pc 4 uptake results in significant cell-killing and drastically reduced post-PDT clonogenicity. Building on this in vitro data, we demonstrate that the EGFR-targeted Pc 4-nanoformulation results in significant intratumoral drug uptake and subsequent enhanced PDT response, in vivo, in SCC-15 xenografts in mice. Altogether our results show significant promise toward a cell-targeted photodynamic nanomedicine for effective treatment of H&N carcinomas.
Authors:
Alyssa Master; Anthony Malamas; Rachna Solanki; Dana M Clausen; Julie L Eiseman; Anirban Sen Gupta
Related Documents :
2547519 - Directed migration of murine and human tumor cells to collagenases and other proteases.
23673539 - U1 adaptor oligonucleotides targeting bcl2 and grm1 suppress growth of human melanoma x...
15150279 - Design of novel and selective inhibitors of urokinase-type plasminogen activator with i...
15387709 - Immunohistochemical expression of matrix metalloproteinases 1, 2, 9, and 14 in dermatof...
19634159 - The role of angiocidin in sarcomas.
7551559 - Epiligrin is decreased in papulonodular basal cell carcinoma tumor nest basement membra...
17563749 - Specific micrornas are downregulated in human thyroid anaplastic carcinomas.
24125979 - Histopathological study of adrenocortical carcinoma with special reference to the weiss...
19362239 - Application of carbon-ion beams or gamma-rays on primary tumors does not change the exp...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2013-04-24
Journal Detail:
Title:  Molecular pharmaceutics     Volume:  10     ISSN:  1543-8392     ISO Abbreviation:  Mol. Pharm.     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-05-06     Completed Date:  2013-12-16     Revised Date:  2014-05-08    
Medline Journal Info:
Nlm Unique ID:  101197791     Medline TA:  Mol Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1988-97     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Biological Transport, Active
Carcinoma, Squamous Cell / drug therapy*,  metabolism,  pathology
Cell Line, Tumor
Chemistry, Pharmaceutical
Drug Delivery Systems
Female
Head and Neck Neoplasms / drug therapy*,  metabolism,  pathology
Humans
Indoles / administration & dosage,  pharmacokinetics
Mice
Mice, SCID
Nanomedicine / methods
Nanoparticles / administration & dosage
Organosilicon Compounds / administration & dosage,  pharmacokinetics
Photochemotherapy / methods*
Photosensitizing Agents / administration & dosage,  pharmacokinetics
Receptor, Epidermal Growth Factor / metabolism
Tumor Stem Cell Assay
Xenograft Model Antitumor Assays
Grant Support
ID/Acronym/Agency:
F31 DE019998/DE/NIDCR NIH HHS; F31-DE019998/DE/NIDCR NIH HHS
Chemical
Reg. No./Substance:
0/Indoles; 0/Organosilicon Compounds; 0/Photosensitizing Agents; 135719-28-7/silicon phthalocyanine; EC 2.7.10.1/EGFR protein, human; EC 2.7.10.1/Receptor, Epidermal Growth Factor
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Excited State Properties of Naphtho-Homologated xxDNA Bases and Effect of Methanol Solution, Deoxyri...
Next Document:  MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cyc...